Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l (Q38827600)
Jump to navigation
Jump to search
scientific article published on 16 October 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l |
scientific article published on 16 October 2015 |
Statements
1 reference
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic l (English)
1 reference
Aradhana Awasthi
1 reference
Janet Ayello
1 reference
Carmella Van de Ven
1 reference
Mona Elmacken
1 reference
Anthony Sabulski
1 reference
Matthew J Barth
1 reference
Myron S Czuczman
1 reference
Humayun Islam
1 reference
Christian Klein
1 reference
Mitchell S Cairo
1 reference
16 October 2015
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference